HPS Pharmacies wish to give notice that Merck Sharpe & Dohme is experiencing a supply interruption for Sinemet® CR as follows:
Sinemet® CR Tablets
Levodopa + Carbidopa 200mg/50mg
Supplies are expected to return to normal by the end of January 2021.
An internationally registered alternative has been approved for supply under Section 19A of the Therapeutic Goods Act 1989, and is listed on the Pharmaceutical Benefits Scheme (PBS). The alternative product is registered in the UK under the brand name, Sinemet® CR 50/200mg Prolonged-Release Tablets. A summary of the differences is shown below.
|Sinemet® CR (Section 19a product)||Sinemet® CR (Australian-registered product)|
|Expression of strength||50mg/200mg
(Carbidopa + levodopa)
(Levodopa + carbidopa)
|Tablet appearance||Peach-coloured, oval shaped, biconvex tablets.
Scored on one side and marked ‘521’ on the other*
|Dappled, purple, oval shaped tablet.
Plain on one side and marked ‘521’ on the other
|Quantity||60 tablets||100 tablets|
*While these tablets have a non-functional score line, they must not be halved. To preserve the slow-release properties of the tablets, Sinemet® CR should be swallowed whole.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Merck Sharp & Dohme on 1800 818 553 or your pharmacist at HPS Pharmacies.